What is the Fiscal Year for Bone Biologics Corp?

Headquarters

Los Angeles, California, United States

Industry

Healthcare, Biotechnology Research Services

Stock Symbol

BBLG

Website

Description

A publicly-held Biotechnology Company that is a spin off of the Musculoskeletal Transplant Foundation (MTF) using technology discovered and licensed from UCLA. Bone Biologics market and focus is in the Regenerative Medicine Orthobiologics space. Bone Biologics was founded in 2004 by University of California professors in collaboration with an Osaka University professor and a USC surgeon and acquired in 2006 by MTF as the major shareholder, who has been the primary funder since the acquisition. The Company’s proprietary, patented platform technology UCB-1™, exclusively licensed from UCLA, has met and surpassed existing standards of care outcomes in completed large animal model (sheep and Rhesus Monkey) studies that have demonstrated that the UCB-1™ technology facilitates superior normal bone growth. The company believes that as a platform technology, UCB-1™ has broad applications in delivering improved outcomes in almost all surgical procedures involved in bone repair and regeneration. Bone Biologics lead product is focused on bone regeneration in human lumbar spinal fusion using our recombinant human protein growth factor, known as Nell-1. Nell-1 is currently under development and progressing toward near term clinical trial studies in human lumbar fusion because Bone Biologics believes that lumbar surgeons are currently underserved by suitable quality outcome results and are receptive to new biological therapies that are target specific. Our mission is to utilize the power of Nell-1 to improve clinical outcomes and reduce total health care delivery costs associated with lumbar spinal fusion. The company is focused on bone repair and regeneration applications and is committed to exploring additional applications of the UCB-1™ technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.